ArticleACS omega2026
Respiratory Syncytial Virus F Protein Adjuvanted with a Carbomer-Based Adjuvant Induces Protective Humoral Response in Mice.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Carbomer-lecithin-based adjuvant Adjuplex has been shown to induce a balanced T cell response and high antibody titers with some of the viral pathogens. Here, we compared the humoral immune response in mice immunized intranasally with respiratory syncytial virus fusion (RSV-F) or glycoprotein (RSV-G) or both using Adjuplex and/or a TLR9 agonist, CpG oligodeoxynucleotide (ODN). Both the adjuvants elicited robust antibody response in mice; however, Adjuplex generated higher levels of neutralizing antibodies as compared to CpG ODN when used with RSV-F protein. Neutralizing antibody titers were associated with reduced RSV load in the lungs of immunized BALB/c mice upon intranasal challenge with the RSV A2 strain. RSV-G alone was insufficient to elicit a strong antibody response with either of the adjuvants, and combining RSV-F and RSV-G did not show any synergistic response in terms of neutralizing antibody titers; however, this combination of antigens elicited a strong mucosal immune response as measured by IgA titers specific to RSV-F and RSV-G in lung tissues. These data suggest that carbomer-based adjuvants can induce a potent and protective humoral and mucosal response when used as an adjuvant for the RSV-F subunit vaccine, and the combination of RSV-F and RSV-G with Adjuplex may further be explored for enhancing the efficacy of RSV vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.